


Welcome to the Injection-Free Revolution



CeQur Simplicity™
[Wear The Revolution™]

A 3-day wearable insulin patch,
clinically proven to reduce A1C and
increase time-in-range (TIR)^{1,2}


Common challenges for patients taking multiple daily injections:



Will only administer insulin at home³



Knowingly miss their insulin injections⁴



Left their insulin at home⁵



People are missing their insulin doses, which can raise A1C and increase risk of diabetes complications.

The solution is CeQur Simplicity™



Convenient

- Easy to apply, wear for up to three days
- Fits into patient's life
- Wearable while showering, sleeping, exercising, and swimming



Discreet

- Wear and dose under clothing
- One click administers two units of insulin
- Thin (<4 stacked quarters), compact (65 x 36 mm), and lightweight (10 gm)



Injection-Free

- Better adherence¹
- Fewer injections: 1 patch replaces 9 mealtime injections, for ~90 fewer injections per month
- Less pain¹

9
out of
10


patients said that they follow their insulin regimen better with CeQur Simplicity.⁶

Use of CeQur Simplicity: Clinically shown to improve glycemic control^{1,2}

With use of CeQur Simplicity,
A1C target goals were achieved

Clinical Outcome Study Findings¹


Mean A1C was reduced to target goal by Week 24




Results were comparable to pens. Consistent A1C <7% supports HEDIS Comprehensive Diabetes Care measure.

After 24 Weeks With CeQur Simplicity,
Patients increased time-in-range (TIR) by 50%²

Baseline:
Time-in-range = 48.4%



After 24 Weeks:
Time-in-range = 74.1%



The International consensus on time-in-range defines clinical target for TIR ≥70%, which is evidenced to be equivalent to an A1C of ≤7%.⁷

CeQur Simplicity is designed for safety



2-button safety mechanism ensures that dosing occurs only when intended⁸



Buttons lock when patch is empty or cannula is occluded⁸



Tactile and audible feedback indicates 2-unit delivery⁸



Adhesive designed to keep patch on skin for up to 3 days



Water-resistant to a depth of 1 meter for up to 30 minutes

Patients prefer CeQur Simplicity

95%

say CeQur Simplicity is easier than a pen or syringe⁶

90%

say mealtime insulin is painless with CeQur Simplicity¹

93%

prefer CeQur Simplicity to pens or syringes*

85%

achieve A1C <8.0⁹



***Disclaimer:** Data from patient assessments after completing the Insulin Delivery System Rating Questionnaire (IDSRQ) at baseline and after two months. Data on file at CeQur.

CeQur Simplicity

Is revolutionizing insulin delivery

84%

say training
was EASY⁶



Most needed <30
minutes of training⁶

Easy to teach, easy to learn¹

Confidence comes quickly⁶


Most patients said that they felt fully comfortable applying the patch after just 1-3 times⁶

Patient training video available on
myceqursimplicity.com/resources-support



What can you expect with training?

Learn more by viewing the CeQur Simplicity
Quick Start Video and Training Checklist



Scan here to watch our
Quick Start Training Video

Getting patients started with CeQur Simplicity

1 Prescribe CeQur Simplicity 2U Patch, 10 Pack

- CeQur Simplicity is covered on most commercial and Medicare Part D insurance plans as a pharmacy benefit



2 Prescribe patients an Inserter Kit containing

- Reusable Inserter
- Quick Start Guide



3 Write a vial of rapid-acting insulin

- Labeled for use with Humalog U-100 and Novolog U-100
- Insulin sold separately

Starter Kits are available from your CeQur representative or by calling the CeQur Care team at

1-888-55-CeQur (1-888-552-3787)



Questions?

We're here to help you
and your patients

For you and your practice:

- Product and Training Support

For your patients:

- Product Support
- Benefit Verification
- Insurance and Access Support

Call CeQur Care for support:

1-888-55-CeQur (1-888-552-3787)

cequrcare@cequr.com

Hours of operation:

Monday–Friday, 9:00 AM–6:00 PM EST

Visit our website:

MyCeQurSimplicity.com

Welcome to **CeQur** Simplicity™

[Wear The Revolution™]

Convenient, Discreet, Injection-Free Dosing

Tactile and audible feedback confirms 2-unit delivery

Buttons lock in “squeezed” position if reservoir is empty, or cannula is occluded

Small, flexible cannula for insulin delivery

Comfortable to wear with rounded corners and a thin, lightweight design



Water-resistant to a depth of 1 meter for up to 30 minutes

Two-button safety mechanism prevents accidental dosing

Holds up to 200 units of rapid-acting insulin, with a minimum fill of 100 units*

Bolus-only patch complements existing basal insulin therapy

*Labeled for use with Humalog® U-100 and NovoLog® U-100. Insulin sold separately.



See previous page for prescribing and ordering information

Visit MyCeQurSimplicity.com

| 1-888-55-CeQur

| Follow us!



REFERENCES: 1. Bergenstal RM, Peyrot M, Dreon DM, et al. Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. *Diabetes Technol Ther.* 2019;21(5):273-285. 2. Bergenstal R, et al. Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles; *Journal of Diabetes Science and Technology* 1–7, 2021. 3. Grabner M, et al. 2013. Using Observational Data to Inform the Design of a Prospective Effectiveness Study for a Novel Insulin Delivery Device, *ClinicoEconomics and Outcomes Research.* 5:471-479. 4. Peyrot M, Rubin R, Kruger D, Travis L. 2010. Correlates of Insulin Injection Omission. *Diabetes Care.* 33(2):240–245. 5. Randlov J, Poulson J. 2008. How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study. *Journal Diabetes Science and Technology.* 2(2):229-35. 6. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association's 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA. 7. Battelino, T., et al., Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care,* 2019. 42(8): p. 1593-1603. 8. Dreon DM, Hannon TM, Cross B, et al. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. *Journal of Diabetes Science and Technology.* 2018 Jul;12(4):817-827. 9. Barry, R, D.O.N. Johns, and B. Rees, 2329-PUB: Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement. *Diabetes,* 2019. 68(Supplement 1): p. 2329-PUB. This is a post-hoc analysis done on Bergenstal Trial.

Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.

© 2022 CeQur SA. All rights reserved. APM-02-0005 Rev C

CeQur Simplicity™
[Wear The Revolution™]